View all CSAC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resources

PER Pulse™ Recap
highlights key points presented in Cancer Summaries and Commentaries™: 2016 Conference Coverage: Advances in the Treatment of Genitourinary (GU) Cancers. First PER Pulse™ Recap focuses on 2 presentations reporting on newly approved agents (eg, nivolumab, cabozantinib) for GU cancers. Second PER Pulse™ Recap focuses on a presentation reporting on atezolizumab, a novel therapy for bladder cancer, as well as several prostate cancer abstracts.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Genentech.

Cancer Summaries and Commentaries™: 2016 Conference Coverage: Advances in the Treatment of Genitourinary Cancers


Release Date: April 29, 2016
Expiration Date: April 29, 2017
Media: Internet - based

Activity Overview

This activity is designed to update physicians on the most clinically impactful data presented at the 2016 Genitourinary Cancers Symposium so that they can assess and prepare to apply these findings to their clinical practice to improve patient care.

CME Activity Table of Contents

  • IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC)  
  • CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) 
  • Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC)
  • NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA
  • Hypofractionated radiotherapy (RT) schedules in patients with low-risk prostate cancer: the RTOG 0415 and CHHiP trials
  • (NGS) Actionable targets in patients with cisplatin-resistant advanced germ cell tumors (GCT)

Instructions For This Activity & Receiving Credit

  • Once you begin the activity, please answer the demographic questions. This will allow you to proceed to the activity.
  • This activity contains one or more interactive question. You may move forward through the activity; however, you may not go back to change answers or review content until you finish the activity.
  • At the end of the activity, an "educational content" link will be available for you to download content in PDF format for your reference.
  • If you close the Web browser after you complete the activity, the "educational content" link will disappear and you will need to review the activity in its entirety to once again access the link to the "educational content."
  • In order to receive a CME certificate, participants must complete the activity.
  • Click on the "Request Credits" link at the end of the activity. Complete the posttest and pass with a score of 70% or higher, complete the evaluation, and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational program is directed toward all attendees of the 2016 Genitourinary Cancers Symposium including medical, surgical, and radiation oncologists and urologists involved in the treatment of patients with GU malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, nuclear medicine physicians, and other health care professionals, interested in the treatment of GU malignancies, may also participate.


Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Summarize recent treatment advances for advanced GU cancers, and their impact on clinical decision making and patient outcomes.
  • Evaluate data on emerging treatments and their potential impact on the future treatment landscape for GU cancers.
  • Evaluate the benefit of clinical trial participation for improving outcomes among patients with GU cancers and limited treatment options.


Faculty, Staff, and Planners' Disclosures

Faculty

Daniel P Petrylak, MD
Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Program
Yale Cancer Center
New Haven, CT

Disclosure: Grant/Research Support: Bayer, Bellicum Pharmaceuticals, Dendreon, Sanofi-Aventis, Johnson & Johnson, Exelixis, Ferring Pharmaceuticals, Millennium Pharmaceuticals, Medivation, Pfizer, Roche Laboratories, Tyme, Inc. Consultant: Bayer, Bellicum Pharmaceuticals, Dendreon, Sanofi-Aventis, Johnson & Johnson, Exelixis, Ferring Pharmaceuticals, Millennium Pharmaceuticals, Medivation, Pfizer, Roche Laboratories, Tyme, Inc.
 

Primo N Lara, Jr, MD
Professor of Medicine
Associate Director for Translational Research
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosure: Honoraria: Pfizer. Consulting/Advisory Role: Clovis Oncology, Pfizer, Teva Pharmaceutical, Halozyme Therapeutics, Novartis, Sanofi, Lpath, Lilly, AstraZeneca, Bayer, Genentech/Roche. Research Funding: Millennium, Polaris, OncoGenex Pharmaceuticals, GlaxoSmithKline, Genentech, Aragon Pharmaceuticals, Janssen Biotech, Heat Biologics.
 

The following individuals have no relevant financial relationships with commercial interests:

The staff of PER®, LLC.


Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.


Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.


Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By